Cyklx is a drug owned by American Genomics Llc. It is protected by 3 US drug patents filed in 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 27, 2039. Details of Cyklx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12403126 | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(13 years from now) | Active |
| US11096922 | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(13 years from now) | Active |
| US11826347 | Anesthetic Composition And Method Of Anesthetizing The Eye |
Mar, 2039
(13 years from now) | Active |
FDA has granted several exclusivities to Cyklx. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Cyklx, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Cyklx.
Exclusivity Information
Cyklx holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Cyklx's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2028 |
US patents provide insights into the exclusivity only within the United States, but
Cyklx is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Cyklx's family patents as well as insights into
ongoing legal events
on those patents.
Cyklx's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cyklx's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 27, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cyklx Generics:
There are no approved generic versions for Cyklx as of now.
About Cyklx
Cyklx is a drug owned by American Genomics Llc. Cyklx uses Articaine Hydrochloride as an active ingredient. Cyklx was launched by Am Genomics in 2025.
Approval Date:
Cyklx was approved by FDA for market use on 15 August, 2025.
Active Ingredient:
Cyklx uses Articaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Articaine Hydrochloride ingredient
Dosage:
Cyklx is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 8% BASE | SOLUTION/DROPS | Discontinued | OPHTHALMIC |